TABLE 1.
The application of small molecule targeted compounds in tumors.
| Compound name | Indication of tumor type | Target |
| Erdafitinib | Urothelial carcinoma | FGFR |
| Everolimus | Breast cancer, Pancreatic cancer, gastrointestinal cancer, gastrointestinal cancer, and lung cancer, Subependymal giant cell astrocytoma, Renal Cell Cancer | mTOR |
| Abemaciclib | Breast cancer | CDK4/6 |
| Alpelisib | Breast cancer | PI3Kα |
| Anastrozole | Breast cancer | Aromatase |
| Exemestane | Breast cancer | Aromatase |
| Toremifene | Breast cancer | Estrogen receptor |
| Fulvestrant | Breast cancer | Estrogen receptor |
| Letrozole | Breast cancer | Estrogen receptor |
| Palbociclib | Breast cancer | CDK4/6 |
| Ribociclib | Breast cancer | CDK4/6 |
| Lapatinib ditosylate | Breast cancer | EGFR,ErbB2,ErbB4 |
| Olaparib | Breast cancer, ovarian cancer, Ovarian epithelial, fallopian tube, or primary peritoneal cancer, Pancreatic cancer, Prostate cancer | PARP1/2 |
| Megestrol acetate | Breast cancer, Endometrial cancer | progestogen Receptor, Androgen Receptor |
| Neratinib maleate | Breast cancer | HER2, EGFR |
| Tamoxifen citrate | Breast cancer, Ductal carcinoma in situ | Estrogen receptor |
| Talazoparib tosylate | Breast cancer | PARP1 |
| Tucatinib | Breast cancer | HER2, ErbB2 |
| Goserelin acetate | Breast cancer, prostate cancer | LHRH agonist |
| Topotecan Hydrochloride | Cervical cancer, Ovarian cancer, Ovarian cancer | Topoisomerase I |
| Irinotecan Hydrochloride | Colorectal cancer, Rectal Cancer | Topoisomerase I |
| Regorafenib | Colorectal cancer, Gastrointestinal stromal tumor, Hepatocellular carcinoma, Rectal Cancer | Ret, Raf-1,VEGFR2 |
| Ziv-Aflibercept | Colorectal cancer, Rectal Cancer | KIT, PDGFRβ, RAF, RET, VEGFR1/2/3 |
| Lenvatinib mesylate | Endometrial carcinoma, Hepatocellular carcinoma, Renal cell carcinoma, Thyroid cancer | VEGFR1/2/3, c-RET |
| Avapritinib | Gastrointestinal stromal tumor | PDGFRα, c-Kit |
| Imatinib mesylate | Acute lymphoblastic leukemia, Chronic eosinophilic leukemia or hypereosinophilic syndrome, Chronic myelogenous leukemia, Dermatofibrosarcoma protuberans, Gastrointestinal stromal tumor, Myelodysplastic/myeloproliferative neoplasms, Systemic mastocytosis | v-Abl,c-Kit, PDGFR |
| Ripretinib | Gastrointestinal stromal tumor | c-Kit,PDGFRα |
| Sunitinib malate | Gastrointestinal stromal tumor, Pancreatic cancer, Renal cell carcinoma | VEGFR2, PDGFRβ, c-kit |
| Axitinib | Renal Cell Cancer | VEGFR1/2/3,PDGFRβ,c-Kit |
| Tivozanib Hydrochloride | Renal Cell Cancer | VEGFR1/2/3 |
| Sorafenib tosylate | Renal Cell Cancer, Hepatocellular carcinoma, Thyroid cancer | Raf-1, VEGFR2, B-Raf |
| Pazopanib Hydrochloride | Renal Cell Cancer | VEGFR1/2/3 |
| Temsirolimus | Renal Cell Cancer | mTOR |
| Dasatinib | Acute Lymphoblastic Leukemia (ALL), Chronic myelogenous leukemia (CML) | Abl, Src, c-Kit |
| Ponatinib Hydrochloride | Acute lymphoblastic leukemia, Chronic myelogenous leukemia (CML) | Abl,PDGFRα,VEGFR2,FGFR1, Src |
| Enasidenib mesylate | Acute myeloid leukemia (AML) | IDH2 |
| Gilteritinib fumarate | Acute myeloid leukemia (AML) | FLT3/AXL |
| Glasdegib maleate | Acute myeloid leukemia | Smoothened (Smo) |
| Ivosidenib | Acute myeloid leukemia (AML) | IDH1 |
| Midostaurin | Acute myeloid leukemia (AML), mast cell leukemia | PKCα/β/γ, Syk, Flk-1 |
| Mitoxantrone Hydrochloride | Acute non-lymphocytic leukemia, Acute non-lymphocytic leukemia, Prostate cancer | Topoisomerase II, PKC |
| Venetoclax | Acute myeloid leukemia, Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) | Bcl-2 |
| Acalabrutinib | Chronic lymphocytic leukemia or small lymphocytic lymphoma, Mantle cell lymphoma | BTK |
| Duvelisib | Chronic lymphocytic leukemia or small lymphocytic lymphoma, Follicular lymphoma | PI3K δ/γ |
| Ibrutinib | Chronic lymphocytic leukemia and small lymphocytic lymphoma, Mantle cell lymphoma, Mantle cell lymphoma, Waldenström macroglobulinemia | BTK, Bmx, CSK, FGR, BRK |
| Idelalisib | Chronic lymphocytic leukemia (CLL), Non-Hodgkin lymphoma (NHL), Follicular B-cell non-Hodgkin lymphoma, Small lymphocytic lymphoma | p110δ |
| Bosutinib | Chronic myelogenous leukemia (CML) | Src/Abl |
| Nilotinib | Chronic myelogenous leukemia (CML) | BCR-ABL |
| Cabozantinib-S-Malate | Hepatocellular carcinoma, Medullary thyroid cancer, Renal cell carcinoma | VEGFR2, c-Met, c-RET, c-Kit |
| Pemigatinib | Cholangiocarcinoma | FGFR |
| Afatinib dimaleate | Non-small cell lung cancer (NSCLC) | EGFR, HER2 |
| Alectinib | Non-small cell lung cancer | ALK |
| Brigatinib | Non-small cell lung cancer | ALK,IGF-1R,FLT3,FLT3, EGFR |
| Capmatinib Hydrochloride | Non-small cell lung cancer | c-Met |
| Ceritinib | Non-small cell lung cancer | ALK |
| Crizotinib | Anaplastic large cell lymphoma, Non-small cell lung cancer | ROS1, c-Met, ALK |
| Dabrafenib mesylate | Anaplastic thyroid cancer, Melanoma, Non-small cell lung cancer | B-Raf |
| Dacomitinib | Non-small cell lung cancer | EGFR, ErbB2, ErbB4 |
| Entrectinib | Non-small cell lung cancer, Solid tumors | TrkA/B/C,ROS1, ALK |
| Erlotinib Hydrochloride | Non-small cell lung cancer, Pancreatic cancer | EGFR |
| Pralsetinib | Medullary thyroid cancer, Non-small cell lung cancer, Thyroid cancer | RET |
| Gefitinib | Non-small cell lung cancer | EGFR |
| Lorlatinib | Non-small cell lung cancer | ALK, ROS1 |
| Trametinib dimethyl sulfoxide | Anaplastic thyroid cancer, Melanoma, Non-small cell lung cancer | MEK |
| Osimertinib mesylate | Non-small cell lung cancer | EGFR |
| Selpercatinib | Medullary thyroid cancer, Non-small cell lung cancer, Thyroid cancer | c-RET |
| Tepotinib Hydrochloride | Non-small cell lung cancer | c-Met |
| Binimetinib | Melanoma | MEK |
| Encorafenib | Colorectal cancer, Melanoma | RAF |
| Vemurafenib | Melanoma | B-RafV600E |
| Plerixafor | Multiple myeloma, Non-Hodgkin lymphoma (NHL) | CXCR4, CXCL12 |
| Panobinostat lactate | Multiple myeloma | HDAC |
| Selinexor | Diffuse large B-cell lymphoma, Multiple myeloma | CRM1 |
| Fedratinib Hydrochloride | Myelofibrosis | JAK2 |
| Ruxolitinib phosphate | Myelofibrosis, Polycythemia vera | JAK1/2 |
| Copanlisib Hydrochloride) | Follicular lymphoma | PI3Kα/β/γ/δ |
| Belinostat | Peripheral T-cell lymphoma | HDAC |
| Zanubrutinib | Mantle cell lymphoma | BTK |
| Romidepsin | Cutaneous T-cell lymphoma, Peripheral T-cell lymphoma | HDAC1, HDAC2 |
| Tazemetostat Hydrobromide | Epithelioid sarcoma, Follicular lymphoma | EZH2 |
| Umbralisib tosylate | Marginal zone lymphoma, Follicular lymphoma | PI3Kδ |
| Vorinostat | Cutaneous T-cell lymphoma | HDAC |
| Rucaparib camsylate | Ovarian epithelial, fallopian tube, or primary peritoneal cancer, Prostate cancer | PARP1 |
| Niraparib tosylate monohydrate | Ovarian epithelial, fallopian tube, or primary peritoneal cancer | PARP1/PARP2 |
| Propranolol hydrochloride | Infantile hemangioma | β-Adrenoceptor |
| Apalutamide | Prostate cancer | androgen receptor |
| Bicalutamide | Prostate cancer | Androgen Receptor |
| Darolutamide | Prostate cancer | androgen receptor |
| Degarelix | Prostate cancer | GnRH receptor |
| Leuprolide acetate | Prostate cancer | GnRHR agonist |
| Enzalutamide | Prostate cancer | androgen-receptor |
| Flutamide | Prostate cancer | androgen-receptor |
| Nilutamide | Prostate cancer | androgen-receptor |
| Relugolix | Prostate cancer | GnRHR |
| Vismodegib | Basal cell carcinoma | Hedgehog |
| Sonidegib | Basal cell carcinoma | Smo |
| Cobimetinib | Melanoma | MEK |
| Larotrectinib sulfate | Solid tumors | TRK |
| Imiquimod | Basal cell carcinoma | TLR7 |
| Vandetanib | Medullary thyroid cancer | VEGFR2 |
| Abiraterone acetate | Prostate cancer | CYP17 |
| Tretinoin | Acute promyelocytic leukemia | Retinoic acid receptor, Retinoid X receptor |
| Sotorasib | Non-small cell lung cancer | K-Ras (G12C) |